US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

300.70

+4.391.48%

Post-market: 300.68-0.0200-0.01%17:05 EDT

Volume:212.54K

Turnover:62.85M

Market Cap:578.69M

PE:- -

High:301.50

Open:291.05

Low:289.32

Close:296.31

52wk High:341.93

52wk Low:71.88

Shares:1.92M

Float Shares:1.92M

Volume Ratio:0.59

T/O Rate:11.04%

Dividend:1.01

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Capricor Therapeutics Shares Rise as FDA Extends Deramiocel Review

Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT)

Aveanna Healthcare's Growth Trajectory Supported by Secular Tailwinds, RBC Says

MT Newswires Live

Wainwright says Capricor’s regulatory risk still high after FDA PDUFA extension

SciSparc Highlights NeuroThera-Clearmind MDMA-PEA Patent Milestone Amid New FDA Psychedelic Guidance

Capricor announces extension of FDA action date for Deramiocel

BioCardia gets FDA confirmation of Helix meeting minutes

Sector Update: Healthcare

MT Newswires Live

Humacyte Plans FDA Filing for Acellular Tissue Engineered Vessel in Dialysis Access

MT Newswires Live

Erasca Wins FDA Fast Track for Pancreatic Therapy

Bao Pharmaceuticals' Trial Application for KJ015 for Injection Approved by US FDA

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and AdaptHealth (AHCO)

Health Care Select Sector SPDR: Pivot points

Analysts Conflicted on These Healthcare Names: Natera (NTRA), Healthequity (HQY) and CSPC Pharmaceutical Group (OtherCHJTF)

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

Analysts Offer Insights on Healthcare Companies: Enovis (ENOV) and Aveanna Healthcare Holdings (AVAH)

Labcorp's Alzheimer's Disease Blood Test Cleared by FDA

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/LABU/news?page=14"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":300.7,"timestamp":1788292800000,"preClose":296.31,"halted":0,"volume":212542,"hourTrading":{"tag":"盘后","latestPrice":300.68,"preClose":300.7,"latestTime":"17:05 EDT","volume":154,"amount":46306.74972,"timestamp":1788296705308,"change":-0.02,"changeRate":-0.000067,"amplitude":0.007149},"delay":0,"changeRate":0.014815564780128873,"floatShares":1924486,"shares":1924486,"eps":0,"marketStatus":"Post-Mkt","change":4.39,"latestTime":"09-01 17:05:17 EDT","open":291.05,"high":301.5,"low":289.32,"amount":62852888.3587,"amplitude":0.041106,"askPrice":301.15,"askSize":2,"bidPrice":299.2,"bidSize":200,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":296.31,"sharesOutstanding":3074486,"nav":295.545,"aum":568772231.45,"dividendRate":0.003351,"bidAskSpread":0.002847,"preHourTrading":{"tag":"盘前","latestPrice":287.9,"preClose":296.31,"latestTime":"09:25 EDT","volume":3856,"amount":1113924.82752,"timestamp":1788269101054,"change":-8.41,"changeRate":-0.028382,"amplitude":0.034741},"postHourTrading":{"tag":"盘后","latestPrice":300.68,"preClose":300.7,"latestTime":"17:05 EDT","volume":154,"amount":46306.74972,"timestamp":1788296705308,"change":-0.02,"changeRate":-0.000067,"amplitude":0.007149},"volumeRatio":0.589675,"impliedVol":0.9266,"impliedVolPercentile":0.5794},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":1924486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.589675,"shares":1924486,"dividePrice":1.0075,"high":301.5,"amplitude":0.041106,"preClose":296.31,"low":289.32,"week52Low":71.88,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":300.7,"committee":0.980198,"eps":0,"divideRate":0.003351,"volume":212542,"delay":0,"ttmEps":0,"open":291.05,"prevYearClose":159.39,"prevWeekClose":295.76,"prevMonthClose":296.31,"prevQuarterClose":292.1,"fiveDayClose":335.54,"twentyDayClose":249.47,"sixtyDayClose":160.26},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:14,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661277336","title":"Capricor Therapeutics Shares Rise as FDA Extends Deramiocel Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2661277336","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661277336?lang=en_us&edition=fundamental","pubTime":"2026-08-24 23:03","pubTimestamp":1787583780,"startTime":"0","endTime":"0","summary":"Capricor Therapeutics shares moved higher on Monday after the Food and Drug Administration extended its review of the biotechnology company's proposed deramiocel cell therapy for Duchenne muscular dystrophy, or DMD, to consider additional study data.Shares of the San Diego company were recently changing hands at $7.03, up almost 12%.Capricor said the FDA extended its target action date for a decision on the resubmitted application for deramiocel to Nov. 22 after Capricor filed 24-month open-label extension data from its pivotal Phase 3 study of the drug, along with additional robustness analyses.Capricor said it submitted the additional information as part of ongoing discussions with the FDA after an FDA advisory panel late last month recommend against approval of the drug, adding that it asked the agency to review the existing and new data in support of a refined proposed indication focused on upper-limb function.The FDA last July rejected Capricor's initial deramiocel application, sa","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CAPR","LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661277313","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661277313","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661277313?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:50","pubTimestamp":1787583009,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT). Lexicon Pharma...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-lexicon-pharmaceuticals-lxrx-and-maxcyte-mxct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-lexicon-pharmaceuticals-lxrx-and-maxcyte-mxct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","BK4581","XLV","LXRX","HCSG","LU0128526141.USD","MXCT","LU0029874061.USD","BK4539","BK4121","BK4585","BK4007","BK4137","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661027228","title":"Aveanna Healthcare's Growth Trajectory Supported by Secular Tailwinds, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2661027228","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661027228?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:47","pubTimestamp":1787582821,"startTime":"0","endTime":"0","summary":"Aveanna Healthcare Holdings  is facing secular tailwinds that back its growth trajectory, as evidenced by the company's increased fiscal 2026 outlook, RBC Capital Markets said in a Friday note.The company's management reiterated its view that private duty nursing, or PDN, appears insulated from potential Medicaid budgetary pressures related to the One Big Beautiful Bill Act, according to the note.Aveanna is also positioned to benefit from the upcoming PDN rate increase in California, as the state's 2027 budget includes a major investment in pediatric private duty nursing rates effective Jan. 1, 2027, RBC said.The investment firm expects the company's private duty services volumes to accelerate in the second half of 2026 and increase materially in 2027.RBC also noted Aveanna's ongoing preferred payor momentum across all of its segments, with the number of preferred-payor agreements nearing or meeting its 2026 targets.RBC raised its price target on Aveanna Healthcare Holdings to $16 from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU0128526141.USD","BK4196","LABU","BK4581","LU0029874061.USD","BK4137","AVAH","XBI","BK4588","XLV","BK4539","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661120272","title":"Wainwright says Capricor’s regulatory risk still high after FDA PDUFA extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2661120272","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661120272?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:30","pubTimestamp":1787581819,"startTime":"0","endTime":"0","summary":"H.C. Wainwright notes that Capricor Therapeutics (CAPR) announced that the FDA extended the PDUFA target action date for deramiocel from August 22 ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wainwright-says-capricors-regulatory-risk-still-high-after-fda-pdufa-extension-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wainwright-says-capricors-regulatory-risk-still-high-after-fda-pdufa-extension-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CAPR","BK4585","BK4588","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661995274","title":"SciSparc Highlights NeuroThera-Clearmind MDMA-PEA Patent Milestone Amid New FDA Psychedelic Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2661995274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661995274?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:47","pubTimestamp":1787579236,"startTime":"0","endTime":"0","summary":"The latest announcement is out from SciSparc Ltd. ( ($SPRC) ). SciSparc Ltd. announced on August 24, 2026, that its subsidiary NeuroThera Labs and ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/scisparc-highlights-neurothera-clearmind-mdma-pea-patent-milestone-amid-new-fda-psychedelic-guidance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/scisparc-highlights-neurothera-clearmind-mdma-pea-patent-milestone-amid-new-fda-psychedelic-guidance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271018","title":"Capricor announces extension of FDA action date for Deramiocel","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271018","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271018?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:35","pubTimestamp":1787578529,"startTime":"0","endTime":"0","summary":"09:30 EDT Capricor announces extension of FDA action date for Deramiocel Published first on TheFly – the ultimate source for real-time, market-movi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/capricor-announces-extension-of-fda-action-date-for-deramiocel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/capricor-announces-extension-of-fda-action-date-for-deramiocel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661775279","title":"BioCardia gets FDA confirmation of Helix meeting minutes","url":"https://stock-news.laohu8.com/highlight/detail?id=2661775279","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661775279?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:00","pubTimestamp":1787576434,"startTime":"0","endTime":"0","summary":"BioCardia (BCDA) announced receipt of FDA confirmation of the outcome of its pre-submission meeting on the Helix Transendocardial Delivery Catheter...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biocardia-gets-fda-confirmation-of-helix-meeting-minutes-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biocardia-gets-fda-confirmation-of-helix-meeting-minutes-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","BK4588","BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661279439","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279439","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661279439?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:58","pubTimestamp":1787576324,"startTime":"0","endTime":"0","summary":"Healthcare stocks were mixed pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF  0.4% higher and the iShares Biotechnology ETF  down 0.2%,Guardant Health  lost a $245.2 million patent infringement lawsuit filed by TwinStrand Biosciences and the University of Washington, TwinStrand said. Guardant Health stock was down more than 1% premarket.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LFSC","GH","STT","HELX","EKG","BK4551","LABU","XLV","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU0061475181.USD","BK4535","IE0034235188.USD","LU0029874061.USD","HCSG","GNOM","LU0128526141.USD","LU1883839398.USD","IE00BGHQF748.EUR","BK4135","LU0320765992.SGD","FDN","LU1894683264.USD","BK4581","LU1894683348.USD","LU0109394709.USD","BK4550","BK4196","PTH","FFOX","LU0889565916.HKD","BK4585","BK4588","IBB","XBI","BK4137","GDOC","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661927919","title":"Humacyte Plans FDA Filing for Acellular Tissue Engineered Vessel in Dialysis Access","url":"https://stock-news.laohu8.com/highlight/detail?id=2661927919","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661927919?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:52","pubTimestamp":1787575979,"startTime":"0","endTime":"0","summary":"Humacyte  said Monday it plans to file in November a supplemental biologics license application with the US Food and Drug Administration to seek approval for the use of its acellular tissue engineered vessel in dialysis access.The company said it will support the filing with data from three phase 3 trials, including a study where female dialysis patients averaged three additional months without a catheter compared with standard of care.The product received regulatory approval in December 2024 for vascular trauma, Humacyte said.Shares of the company were up 6.4% in Monday premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4563","BK4585","BK4139","BK4588","HUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661727976","title":"Erasca Wins FDA Fast Track for Pancreatic Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2661727976","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661727976?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:48","pubTimestamp":1787575690,"startTime":"0","endTime":"0","summary":"Erasca ( ($ERAS) ) has shared an announcement. On August 24, 2026, Erasca, Inc. reported that the U.S. Food and Drug Administration granted Fast Tr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/erasca-wins-fda-fast-track-for-pancreatic-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/erasca-wins-fda-fast-track-for-pancreatic-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ERAS","BK4539","BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661627930","title":"Bao Pharmaceuticals' Trial Application for KJ015 for Injection Approved by US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2661627930","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661627930?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:40","pubTimestamp":1787575215,"startTime":"0","endTime":"0","summary":"Shanghai Bao Pharmaceuticals'  investigational new drug application for the clinical trials of KJ015 for injection was approved by the U.S. Food and Drug Administration.The injection is a subcutaneous formulation of dual epitope-targeting HER2 bispecific antibody, according to a Monday Hong Kong bourse filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","LABU","02659","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661625279","title":"Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and AdaptHealth (AHCO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661625279","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661625279?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:40","pubTimestamp":1787575205,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on United Therapeutics (UTHR) and AdaptHealth (AHCO) wi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-united-therapeutics-uthr-and-adapthealth-ahco-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-united-therapeutics-uthr-and-adapthealth-ahco-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LABU","BK4137","HCSG","XLV","BK4588","LU1571399168.USD","BK4175","LU1699723380.USD","BK4139","BK4585","LU0029874061.USD","UTHR","XBI","LU0128526141.USD","BK4532","AHCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661279560","title":"Health Care Select Sector SPDR: Pivot points","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279560","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661279560?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:37","pubTimestamp":1787575027,"startTime":"0","endTime":"0","summary":"The following are the pivot points for the Health Care Select Sector SPDR (XLV). Pivot High: $177.02, Pivot Low: $173.21. These were calculated usi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/health-care-select-sector-spdr-pivot-points-thefly-news-128?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/health-care-select-sector-spdr-pivot-points-thefly-news-128?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","XLV","BK4581","LABU","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661284276","title":"Analysts Conflicted on These Healthcare Names: Natera (NTRA), Healthequity (HQY) and CSPC Pharmaceutical Group (OtherCHJTF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661284276","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661284276?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:20","pubTimestamp":1787574012,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Natera (NTRA), Healthequity (HQY) and CSPC Pharmaceutical Group (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-natera-ntra-healthequity-hqy-and-cspc-pharmaceutical-group-otherchjtf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-natera-ntra-healthequity-hqy-and-cspc-pharmaceutical-group-otherchjtf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","LU2324357040.USD","LU0963586101.USD","LU0029874061.USD","NTRA","BK4137","LU1169590202.USD","BK4588","BK4139","LU0053671581.USD","LU0345770993.USD","LABU","LU2095319765.USD","LU2210149790.SGD","BK4585","BK4154","LU1169589451.USD","GNOM","LU2065171402.SGD","LU1064131342.USD","HCSG","BK4581","LU0012050646.USD","HELX","XBI","LU2065171311.SGD","LU2264538146.SGD","XLV","LU0345770308.USD","LU1988902786.USD","LU0106261612.USD","LU2065170008.USD","LU2065169927.USD","HQY","LU2210150020.SGD","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661279661","title":"New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279661","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661279661?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:15","pubTimestamp":1787573700,"startTime":"0","endTime":"0","summary":"DUBLIN and BRIDGEWATER, N.J., Aug.  24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349705/18362/en/new-analyses-from-reduce-it-and-epa-mechanistic-data-to-be-presented-at-the-european-society-of-cardiology-esc-congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4139","BK4090","BK4588","EPV","TG","BK4585","BK4153","AMRN","IPE","VGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661575279","title":"Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2661575279","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661575279?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:03","pubTimestamp":1787572980,"startTime":"0","endTime":"0","summary":"U.S. publication of the patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration with Neurothera Labs Inc. as the FDA intr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349697/0/en/clearmind-advances-mdma-n-acylethanolamines-ip-for-the-treatment-of-ptsd-amid-rising-u-s-federal-support-for-psychedelic-innovation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1481599808.USD","LU2463526074.USD","IE00B3T34201.USD","LABU","LU1169589451.USD","LU1481600234.SGD","IP","WOOD","LU1487256676.USD","BK4585","LU1169590202.USD","BK4588","USRD","BK4136","CUT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661279504","title":"Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279504","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661279504?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:00","pubTimestamp":1787572800,"startTime":"0","endTime":"0","summary":"– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 – – Supplemental BLA will be supported by results from three Phase ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349666/0/en/humacyte-confirms-plans-for-atev-supplemental-bla-filing-for-dialysis-access-following-fda-discussions.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AV","BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275904","title":"Analysts Offer Insights on Healthcare Companies: Enovis (ENOV) and Aveanna Healthcare Holdings (AVAH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275904","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275904?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:40","pubTimestamp":1787571627,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Enovis (ENOV) and Aveanna Healthcare Holdings (AVA...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-enovis-enov-and-aveanna-healthcare-holdings-avah-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-enovis-enov-and-aveanna-healthcare-holdings-avah-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z6F94.USD","XBI","XLV","BK4082","ENOV","LABU","BK4539","LU2065732104.USD","BK4588","AVAH","BK4196","BK4581","IE0034390439.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275622","title":"Labcorp's Alzheimer's Disease Blood Test Cleared by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275622","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275622?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:39","pubTimestamp":1787571550,"startTime":"0","endTime":"0","summary":"Labcorp  said Monday that its blood test that detects Alzheimer's disease is now available after receiving clearance from the US Food and Drug Administration.The company said its Elecsys pTau-217 test, developed by Roche Diagnostics, helps identify amyloid pathology associated with Alzheimer's disease in people aged 55 and older with signs, symptoms, or complaints of cognitive decline.The test, according to Labcorp, is the only FDA-cleared single-biomarker blood test to rule in and rule out amyloid pathology in specialty and primary care settings.Labcorp said it expects the test to be available nationwide in the coming months.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4196","LU2237438978.USD","LU1059921491.USD","LU0742534661.SGD","LU0048573561.USD","BK4550","LABU","BK4585","LU0251131958.USD","BK4588","LH","LU0006061336.USD","LU0251142724.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275889","title":"Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275889","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275889?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:20","pubTimestamp":1787570417,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Hea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eloxx-pharmaceuticals-elox-cingulate-inc-cing-and-agilon-health-agl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eloxx-pharmaceuticals-elox-cingulate-inc-cing-and-agilon-health-agl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","ELOX","XBI","BK4137","BK4588","CING","LU0029874061.USD","BK4196","BK4585","BK4539","HCSG","AGL","LABU","LU0128526141.USD","XLV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":21,"pageCount":14,"totalSize":411,"code":"91000000","status":"200"}]}}